ophthalmology-summit-2018-scientifictracks-abstracts

31 / 36

Page 71
conferenceseries.com
Volume 9 J Clin Exp Ophthalmol, an open access journal
ISSN: 2155-9570 Ophthalmology Summit 2018
February 26-27, 2018
February 26-27, 2018 | Berlin, Germany
19th Global Ophthalmology Summit
The role of corneal densitometry in the ophthalmic examination of Fabry's disease, and in the follow-
up of the effect of enzyme replacement therapy
Rita Szechey, Kinga Kranitz and Zsolt Nagy-Zoltan
Head of the University Department
Objective: To study the corneal densitometric values of Fabry's disease with typical corneal vertigo, and to monitor the effect
of the enzyme replacement therapy with a Scheimpflug camera
Patients and Methods: The corneal densitometric values of 6 patients with Fabry's disease were compared to the eyes of
5 healthy subjects. In a hemizygotic male patient and heterozygous female patient, 2 studies were performed on both eyes
with 2 years follow-up during the therapy. Measurements were performed with Scheimpflug camera Pentacam HR (Oculus
Optikgerate) The results were given in standardized grayscale units (GSU).
Results: The mean densitometric value for the entire cornea was significantly higher in the patient group compared to the
control group. In the central layer of the corneal surface of 120 μm the mean densitometric values measured in the deepest
60 μm layer were significantly higher in Fabry patients. In the densitometric values of hemizygotic men and heterozygous
women, the superficial 120 μm layer was found to be significantly different. In two years of enzyme replacement therapy, the
density values for total cornea significantly and a significant decrease in corneal surface 120 μm and the lower 60 μm .
Conclusions: 1. Fabry's disease with cornea verticillatus and subepthelial haze significantly increased densitometric values
compared to normal control eyes. 2. Enzyme replacement therapy resulted in a significant decrease in Fabry's disease in corneal
densitometry. In the future, the method in examining the efficacy of therapy, as well as in the standardisation of the ophthalmic
parameters of the scoring system, can play a significant role.
Biography
Rita Szechey: Besides my other activities (ophthalmologic rehabilitation: vision and eyelid surgeries) I work as a consultant for Fabry -patients at the Budapest
Semmelweis University. I am a member of the Fabry Patient Organization and I am committed to patient treatment and the research of the disease.
Rita Szechey et al., J Clin Exp Ophthalmol 2018, Volume 9
DOI: 10.4172/2155-9570-C1-078